{"success":true,"data":{"pressRelease":{"id":"95011","rtpr_id":"nNFC1GSXDf","ticker":"ROVA","exchange":"","all_tickers":["ROVA"],"title":"Altrova Health Provides Corporate Update: New OTCQB Symbol, O-Spray Commercial Progress, Additional NIRLAB Device Sale, and Rapid Detection Strip Expansion","author":"Newsfile Corp","published_at":"2026-07-22T11:08:14.107Z","article_body":"Toronto, Ontario--(Newsfile Corp. - July 22, 2026) - Altrova Health Inc. (CSE:\nROVA) (OTCQB: ATVHF) (FSE: WF8) (\"Altrova Health\" or the \"Company\") is pleased\nto provide shareholders with an update across several areas of its business.\n\nNew OTCQB Trading Symbol\n\nThe Company's common shares commenced trading on the OTCQB under the new\nticker symbol \"ATVHF,\" effective as of market open on July 17, 2026, replacing\nthe Company's prior symbol \"SSPLF.\" The change does not affect the Company's\nshare structure, CUSIP, or its listing on the Canadian Securities Exchange,\nwhere shares continue to trade under \"ROVA.\" The new symbol aligns the\nCompany's US trading identity with the Altrova Health name and brand.\n\nO-Spray Commercial Update\n\nThe Company continues to advance the commercial rollout of its O-Spray product\nline. Since launch, Altrova Health has been engaged in ongoing discussions\nwith prospective distribution and licensing partners to expand O-Spray's reach\nacross retail and healthcare practitioner channels. Management believes these\npartnership discussions, if concluded, would meaningfully accelerate O-Spray's\nmarket penetration, and the Company looks forward to providing further updates\nas agreements are finalized.\n\nAdditional NIRLAB Device Sale\n\nThe Company is pleased to announce the sale of an additional NIRLAB SA\n(\"NIRLAB\") NIRLIGHT drug analysis device to a First Nation community,\nexpanding the device's presence within Indigenous community safety\ninitiatives. This sale builds on Altrova Health's growing footprint with\nNIRLAB across Canada and reflects continued demand for rapid, non-invasive\ndrug analysis tools among community health and public safety stakeholders.\n\nRapid Detection Strip Portfolio: Drug Lab 118 Ltd. (Drug Lab US)\n\nThe Company is also advancing a new commercial strategy for its rapid\ndetection strip portfolio through its wholly owned subsidiary, Drug Lab 118\nLtd. (\"Drug Lab US\"), marking a rebrand and commercial relaunch of the product\nline under the Altrova Health umbrella.\n\nDrug Lab US's core product lines, Drink Detective, Drug Detective, and\nFentanyl Detective, provide rapid, user-friendly field detection tools\naddressing two urgent public health priorities: the rise in illicit drink\nspiking and the ongoing fentanyl crisis. Drink Detective is engineered to\nidentify illicit substances and sedatives concealed in drinks, Drug Detective\noffers surface-testing to detect trace drug residue on personal property and\npackaging, and Fentanyl Detective delivers rapid, accurate detection of\nfentanyl and its analogs in high-risk environments.\n\nUnder its new commercial strategy, the Company is focused on scaling\ndistribution of this portfolio across the United States and Canada, targeting\neducational institutions, hospitality operators, and municipal and public\nsafety stakeholders.\n\nAdvisory Board Update\n\nThe Company is pleased to announce it is onboarding two new advisors:\nCastlewood Capital Corporation and Blaise Yerly.\n\nJason Libenson, President and Chief Operating Officer of Castlewood Capital\nCorporation, brings over ten years of experience in financial services, having\nheld senior roles with several asset managers and raised capital across mutual\nfunds, hedge funds, and flow-through fund structures. He has also served on\nthe boards of various public companies. Mr. Libenson holds a Bachelor of\nCommerce from Concordia University and resides in Toronto.\n\nBlaise Yerly brings over 30 years of experience in Canadian public markets as\nboth an investor and director. He previously served as a director and Chairman\nof Aquiline Resources, acquired by Pan American Silver in 2009 for over $620\nmillion in stock, and as a director of Treasury Metals (now NeXGold Mining)\nfrom 2008 to 2018 and Cypherpunk Holdings (now Sol Strategies Inc.) from 2017\nto 2021. Mr. Yerly has served as Executive Chairman of Wacyba Ltd, a\nSwiss-based family holding company, since 2008, and has previously built and\nsold a heavy equipment distribution business in sub-Saharan Africa along with\na related asset-based finance company.\n\n\"Jason and Blaise bring exactly the kind of capital markets and public company\nexperience we want around the table as Altrova Health scales,\" said Geoff\nBenic, Chief Executive Officer of Altrova Health. \"Jason's track record\nraising capital across a range of investment vehicles, paired with Blaise's\nthree decades building and directing public companies, gives us valuable\nperspective as we advance our commercial strategy across O-Spray, NIRLAB, and\nour rapid detection portfolio.\"\n\nThe Company also confirms that statements in its July 2, 2026 press release\nregarding Raf Souccar continuing in an advisory capacity following his\nresignation as Chairman were included in error. Mr. Souccar is not serving,\nand has not agreed to serve, in any capacity with the Company.\n\nAbout Altrova Health Inc.\n\nAltrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) is a Canadian public\ncompany building a growing portfolio of health solutions across detection,\nprotection, treatment, and wellness. The Company's current product portfolio\nincludes exclusive Canadian distribution rights for the NIRLAB SA (\"NIRLAB\")\nNIRLIGHT drug analysis device, the ToxiShield fentanyl and drink-spiking\ndetection product line, and the O-Spray product line, alongside the rapid\ndetection strip portfolio of its subsidiary Drug Lab 118 Ltd.\n\nFor more information, please visit: www.altrovahealth.com\n\nOn behalf of the Board of Directors of Altrova Health Inc.\n\n\"Geoff Benic\"\nGeoff Benic, CEO\n\nMedia & Investor Contact:\nAltrova Health Inc.\nEmail: info@altrovahealth.com\nGeoff Benic, Chief Executive Officer\nEmail: geoff@altrovahealth.com\nPhone: +1 647-880-7314\nWebsite: www.altrovahealth.com\n\nThe Canadian Securities Exchange does not accept responsibility for the\nadequacy or accuracy of this release.\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis news release contains \"forward-looking information\" and \"forward-looking\nstatements\" within the meaning of applicable Canadian securities legislation,\nincluding statements regarding the Company's trading under its new OTCQB\nsymbol, anticipated partnership and licensing discussions for O-Spray,\nexpected commercial expansion of NIRLAB and Drug Lab US's rapid detection\nstrip portfolio, and the Company's Board composition. Forward-looking\nstatements are based on the opinions and estimates of management as of the\ndate such statements are made and are subject to known and unknown risks,\nuncertainties, and other factors that may cause actual results to differ\nmaterially from those expressed or implied by such statements, including risks\nrelating to the completion of partnership or licensing agreements, market\nadoption of the Company's products, regulatory factors, and general business\nand economic conditions. Although the Company believes that the assumptions\nand factors used in preparing these forward-looking statements are reasonable,\nundue reliance should not be placed on them, as they only apply as of the date\nof this news release. The Company does not undertake any obligation to update\nor revise any forward-looking statements, whether as a result of new\ninformation, future events, or otherwise, except as required by applicable\nsecurities laws.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/306031","article_body_html":"","raw_payload":{"data":{"id":"nNFC1GSXDf","title":"Altrova Health Provides Corporate Update: New OTCQB Symbol, O-Spray Commercial Progress, Additional NIRLAB Device Sale, and Rapid Detection Strip Expansion","author":"Newsfile Corp","ticker":"ROVA","created":"2026-07-22T11:08:14.107Z","tickers":["ROVA"],"exchange":"","article_body":"Toronto, Ontario--(Newsfile Corp. - July 22, 2026) - Altrova Health Inc. (CSE:\nROVA) (OTCQB: ATVHF) (FSE: WF8) (\"Altrova Health\" or the \"Company\") is pleased\nto provide shareholders with an update across several areas of its business.\n\nNew OTCQB Trading Symbol\n\nThe Company's common shares commenced trading on the OTCQB under the new\nticker symbol \"ATVHF,\" effective as of market open on July 17, 2026, replacing\nthe Company's prior symbol \"SSPLF.\" The change does not affect the Company's\nshare structure, CUSIP, or its listing on the Canadian Securities Exchange,\nwhere shares continue to trade under \"ROVA.\" The new symbol aligns the\nCompany's US trading identity with the Altrova Health name and brand.\n\nO-Spray Commercial Update\n\nThe Company continues to advance the commercial rollout of its O-Spray product\nline. Since launch, Altrova Health has been engaged in ongoing discussions\nwith prospective distribution and licensing partners to expand O-Spray's reach\nacross retail and healthcare practitioner channels. Management believes these\npartnership discussions, if concluded, would meaningfully accelerate O-Spray's\nmarket penetration, and the Company looks forward to providing further updates\nas agreements are finalized.\n\nAdditional NIRLAB Device Sale\n\nThe Company is pleased to announce the sale of an additional NIRLAB SA\n(\"NIRLAB\") NIRLIGHT drug analysis device to a First Nation community,\nexpanding the device's presence within Indigenous community safety\ninitiatives. This sale builds on Altrova Health's growing footprint with\nNIRLAB across Canada and reflects continued demand for rapid, non-invasive\ndrug analysis tools among community health and public safety stakeholders.\n\nRapid Detection Strip Portfolio: Drug Lab 118 Ltd. (Drug Lab US)\n\nThe Company is also advancing a new commercial strategy for its rapid\ndetection strip portfolio through its wholly owned subsidiary, Drug Lab 118\nLtd. (\"Drug Lab US\"), marking a rebrand and commercial relaunch of the product\nline under the Altrova Health umbrella.\n\nDrug Lab US's core product lines, Drink Detective, Drug Detective, and\nFentanyl Detective, provide rapid, user-friendly field detection tools\naddressing two urgent public health priorities: the rise in illicit drink\nspiking and the ongoing fentanyl crisis. Drink Detective is engineered to\nidentify illicit substances and sedatives concealed in drinks, Drug Detective\noffers surface-testing to detect trace drug residue on personal property and\npackaging, and Fentanyl Detective delivers rapid, accurate detection of\nfentanyl and its analogs in high-risk environments.\n\nUnder its new commercial strategy, the Company is focused on scaling\ndistribution of this portfolio across the United States and Canada, targeting\neducational institutions, hospitality operators, and municipal and public\nsafety stakeholders.\n\nAdvisory Board Update\n\nThe Company is pleased to announce it is onboarding two new advisors:\nCastlewood Capital Corporation and Blaise Yerly.\n\nJason Libenson, President and Chief Operating Officer of Castlewood Capital\nCorporation, brings over ten years of experience in financial services, having\nheld senior roles with several asset managers and raised capital across mutual\nfunds, hedge funds, and flow-through fund structures. He has also served on\nthe boards of various public companies. Mr. Libenson holds a Bachelor of\nCommerce from Concordia University and resides in Toronto.\n\nBlaise Yerly brings over 30 years of experience in Canadian public markets as\nboth an investor and director. He previously served as a director and Chairman\nof Aquiline Resources, acquired by Pan American Silver in 2009 for over $620\nmillion in stock, and as a director of Treasury Metals (now NeXGold Mining)\nfrom 2008 to 2018 and Cypherpunk Holdings (now Sol Strategies Inc.) from 2017\nto 2021. Mr. Yerly has served as Executive Chairman of Wacyba Ltd, a\nSwiss-based family holding company, since 2008, and has previously built and\nsold a heavy equipment distribution business in sub-Saharan Africa along with\na related asset-based finance company.\n\n\"Jason and Blaise bring exactly the kind of capital markets and public company\nexperience we want around the table as Altrova Health scales,\" said Geoff\nBenic, Chief Executive Officer of Altrova Health. \"Jason's track record\nraising capital across a range of investment vehicles, paired with Blaise's\nthree decades building and directing public companies, gives us valuable\nperspective as we advance our commercial strategy across O-Spray, NIRLAB, and\nour rapid detection portfolio.\"\n\nThe Company also confirms that statements in its July 2, 2026 press release\nregarding Raf Souccar continuing in an advisory capacity following his\nresignation as Chairman were included in error. Mr. Souccar is not serving,\nand has not agreed to serve, in any capacity with the Company.\n\nAbout Altrova Health Inc.\n\nAltrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) is a Canadian public\ncompany building a growing portfolio of health solutions across detection,\nprotection, treatment, and wellness. The Company's current product portfolio\nincludes exclusive Canadian distribution rights for the NIRLAB SA (\"NIRLAB\")\nNIRLIGHT drug analysis device, the ToxiShield fentanyl and drink-spiking\ndetection product line, and the O-Spray product line, alongside the rapid\ndetection strip portfolio of its subsidiary Drug Lab 118 Ltd.\n\nFor more information, please visit: www.altrovahealth.com\n\nOn behalf of the Board of Directors of Altrova Health Inc.\n\n\"Geoff Benic\"\nGeoff Benic, CEO\n\nMedia & Investor Contact:\nAltrova Health Inc.\nEmail: info@altrovahealth.com\nGeoff Benic, Chief Executive Officer\nEmail: geoff@altrovahealth.com\nPhone: +1 647-880-7314\nWebsite: www.altrovahealth.com\n\nThe Canadian Securities Exchange does not accept responsibility for the\nadequacy or accuracy of this release.\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis news release contains \"forward-looking information\" and \"forward-looking\nstatements\" within the meaning of applicable Canadian securities legislation,\nincluding statements regarding the Company's trading under its new OTCQB\nsymbol, anticipated partnership and licensing discussions for O-Spray,\nexpected commercial expansion of NIRLAB and Drug Lab US's rapid detection\nstrip portfolio, and the Company's Board composition. Forward-looking\nstatements are based on the opinions and estimates of management as of the\ndate such statements are made and are subject to known and unknown risks,\nuncertainties, and other factors that may cause actual results to differ\nmaterially from those expressed or implied by such statements, including risks\nrelating to the completion of partnership or licensing agreements, market\nadoption of the Company's products, regulatory factors, and general business\nand economic conditions. Although the Company believes that the assumptions\nand factors used in preparing these forward-looking statements are reasonable,\nundue reliance should not be placed on them, as they only apply as of the date\nof this news release. The Company does not undertake any obligation to update\nor revise any forward-looking statements, whether as a result of new\ninformation, future events, or otherwise, except as required by applicable\nsecurities laws.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/306031"},"type":"article","timestamp":"2026-07-22T11:08:14.169119906Z","server_sent_at_ms":1784718494169},"received_at":"2026-07-22T11:08:14.220Z","source_url":"https://www.newsfilecorp.com/release/306031"},"analysis":{"id":"84057","press_release_id":"95011","analysis_json":{"industry":{"label":"Health Care Equipment & Services","sector":"Health Care"},"redFlags":["Correction required: Previous press release erroneously stated former Chair Raf Souccar was serving as advisor; he is not affiliated with the company","Commercial updates rely on 'ongoing discussions' with no finalized agreements announced"],"eventType":"operations_update","narrative":"Altrova Health shares on the OTCQB market began trading under the new symbol \"ATVHF\" effective July 17, aligning the US trading identity with the company name, while the CSE listing remains \"ROVA.\"\n\nThe company reported continued commercial progress for its O-Spray product line and the sale of an additional NIRLAB device to a First Nation community, alongside a rebranding strategy for its Drug Lab US rapid detection subsidiary.\n\nManagement appointed two new advisors, Jason Libenson and Blaise Yerly, to support capital markets and governance strategy, while correcting a prior statement that former Chair Raf Souccar would remain as an advisor.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine update; low materiality."},"keyFigures":null,"quotedText":"Jason and Blaise bring exactly the kind of capital markets and public company experience we want around the table as Altrova Health scales","namedEntities":{"people":[{"name":"Jason Libenson","role":"Advisor, President and COO of Castlewood Capital"},{"name":"Blaise Yerly","role":"Advisor"},{"name":"Geoff Benic","role":"CEO"},{"name":"Raf Souccar","role":"Former Chairman"}],"products":["O-Spray","NIRLIGHT","Drink Detective","Drug Detective","Fentanyl Detective","ToxiShield"],"companies":[{"name":"Altrova Health Inc.","ticker":"ROVA"},{"name":"NIRLAB SA","relationship":"partner/supplier"},{"name":"Drug Lab 118 Ltd.","relationship":"subsidiary"},{"name":"Castlewood Capital Corporation","relationship":"appointed advisor firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine corporate update with administrative changes (OTCQB ticker), minor operational progress (discussions, single device sale), and advisor appointments. No financial results or material commercial agreements were announced."},"tickerRelevance":{"others":[],"primary":"ROVA"},"globalImportance":10,"audienceRelevance":10,"eventTypeSecondary":["ticker_change","board_change"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"administrative_update","revenueImpact":"none_disclosed"}},"event_type":"operations_update","event_type_secondary":["ticker_change","board_change"],"sentiment":"neutral","material_impact_score":1,"narrative":"Altrova Health shares on the OTCQB market began trading under the new symbol \"ATVHF\" effective July 17, aligning the US trading identity with the company name, while the CSE listing remains \"ROVA.\"\n\nThe company reported continued commercial progress for its O-Spray product line and the sale of an additional NIRLAB device to a First Nation community, alongside a rebranding strategy for its Drug Lab US rapid detection subsidiary.\n\nManagement appointed two new advisors, Jason Libenson and Blaise Yerly, to support capital markets and governance strategy, while correcting a prior statement that former Chair Raf Souccar would remain as an advisor.","key_figures":null,"named_entities":{"people":[{"name":"Jason Libenson","role":"Advisor, President and COO of Castlewood Capital"},{"name":"Blaise Yerly","role":"Advisor"},{"name":"Geoff Benic","role":"CEO"},{"name":"Raf Souccar","role":"Former Chairman"}],"products":["O-Spray","NIRLIGHT","Drink Detective","Drug Detective","Fentanyl Detective","ToxiShield"],"companies":[{"name":"Altrova Health Inc.","ticker":"ROVA"},{"name":"NIRLAB SA","relationship":"partner/supplier"},{"name":"Drug Lab 118 Ltd.","relationship":"subsidiary"},{"name":"Castlewood Capital Corporation","relationship":"appointed advisor firm"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-22T12:32:16.497Z","global_importance":10,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"administrative_update","revenueImpact":"none_disclosed"}},"durationMs":283039,"modelName":"glm-4.7"}}